AVITA Medical, Inc. (RCEL): Price and Financial Metrics

AVITA Medical, Inc. (RCEL): $20.64

0.05 (+0.24%)

POWR Rating

Component Grades













RCEL Stock Price Chart Interactive Chart >

Price chart for RCEL

RCEL Price/Volume Stats

Current price $20.64 52-week high $32.10
Prev. close $20.59 52-week low $16.87
Day low $20.45 Volume 565,400
Day high $21.11 Avg. volume 156,123
50-day MA $19.36 Dividend yield N/A
200-day MA $22.12 Market Cap 512.76M

AVITA Medical, Inc. (RCEL) Company Bio

AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.

RCEL Latest News Stream

Event/Time News Detail
Loading, please wait...

RCEL Latest Social Stream

Loading social stream, please wait...

View Full RCEL Social Stream

Latest RCEL News From Around the Web

Below are the latest news stories about AVITA Medical Inc that investors may wish to consider to help them evaluate RCEL as an investment opportunity.

AVITA Medical raises fiscal Q4 revenue outlook above consensus

AVITA Medical (RCEL) announces preliminary financial results for fiscal Q4 2021. For Q4 ending June 30, 2021, the company is raising its guidance to be in range of $9.5M to $9.7M (consensus $7.06M), consisting of $6.0M to $6.2M of RECELL commercial revenue and $3.5M of RECELL revenue associated with BARDA.The company's previously...

Seeking Alpha | June 16, 2021

AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results

VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021. For the fiscal quarter ending June 30, 2021, AVITA Medical has to date realized total revenue in excess of its

Yahoo | June 15, 2021

FDA gives green light to Avita''s ''spray-on'' burns treatment for children, shares gain - Stockhead

Burns treatment company Avita Medical (ASX:AVH) won further approval from the FDA to treat a wider variety of burns and in paediatric patients too.

Stockhead | June 10, 2021

BTIG Thinks Avita Medicals Stock is Going to Recover

In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Avita Medical (RCEL), with a price target of $37.00. The post BTIG Thinks Avita Medicals Stock is Going to Recover appeared first on Smarter Analyst .

Smarter Analyst | June 10, 2021

Why the AVITA (ASX:AVH) share price is booming

The AVITA Medical Inc (ASX:AVH) share price is up more than 14% after getting some positive news from the US FDA. The information in this article contains general financial advice only and is authorised by The Rask Group Pty Ltd (ABN: 36 622 810 995). That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you do not know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please take a moment to read our Financial Services Guide (FSG) . The post Why the AVITA (ASX:AVH) share price is booming appeared first on Rask Media .

Rask Australia (Media) | June 10, 2021

Read More 'RCEL' Stories Here

RCEL Price Returns

1-mo 12.66%
3-mo -7.24%
6-mo 17.54%
1-year -35.50%
3-year 374.43%
5-year 162.93%
YTD 11.09%
2020 -59.16%
2019 712.50%
2018 4.67%
2017 -41.82%
2016 24.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8597 seconds.